BYSI

MKT CAP:$70M

BeyondSpring Inc.

Market Cap

$70M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.66+$0.05 (+3.11%)

Apr 23, 2026

Company Details

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding age...

CEO

Lan Huang

IPO Date

Mar 9, 2017

Website

www.beyondspringpharma.com

Key Metrics TTM

Revenue

$1M

-11.2% YoY

Net Income

-$14M

EPS (Diluted)

-$0.36

Free Cash Flow

-$6M

Revenue / Share

$0.03

Gross Margin

100.0%

Operating Margin

-1111.2%

Net Margin

-998.8%

FCF Margin

-426.9%

P/S

51.0x

P/E

—

Earnings Reports

Q3 2025

May 12, 2026

PENDING

Q2 2025

Aug 13, 2025

$0-100.0%EPS -$0.04

FY 2024

Mar 27, 2025

$0EPS -$0.28

Q2 2024

Aug 29, 2024

$500.0K+14.3%EPS -$0.09

FY 2023

Apr 29, 2024

$0EPS -$0.54

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 19	$0	$0	-$15M
Q1 20	$0	$0	-$17M
Q3 20	$0	$0	-$15M
Q1 21	$338.0K	$338.0K	-$17M
Q1 22	$338.0K	$338.0K	-$10M
Q2 22	$338.0K	$338.0K	-$10M
Q3 22	$337.5K	$337.5K	-$8M
Q4 22	$337.5K	$337.5K	-$8M
Q1 23	$437.5K	$437.5K	-$7M
Q2 23	$437.5K	$437.5K	-$7M
Q3 23	$438.0K	$438.0K	-$5M
Q4 23	$438.0K	$438.0K	-$5M
Q2 24	$500.0K	$500.0K	-$4M
Q2 25	$0	$0	-$2M

Valuation

Quarter	P/S	P/E
Q4 19	—	—
Q1 20	—	—
Q3 20	—	—
Q1 21	1224.4x	—
Q1 22	132.9x	—
Q2 22	55.1x	—
Q3 22	27.2x	—
Q4 22	54.8x	—
Q1 23	31.4x	—
Q2 23	29.2x	—
Q3 23	18.9x	—
Q4 23	20.9x	—
Q2 24	54.1x	—
Q2 25	68.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 19	-$13M	-$13M
Q1 20	-$11M	-$11M
Q3 20	-$11M	-$11M
Q1 21	-$19M	-$19M
Q1 22	$0	$0
Q2 22	$0	$0
Q3 22	$0	$0
Q4 22	$838.0K	$4M
Q1 23	$0	$0
Q2 23	$0	$0
Q3 23	$0	$0
Q4 23	$0	$0
Q2 24	$0	$0
Q2 25	-$6M	-$6M

Capital Expenditures

Quarter	CapEx
Q4 19	$12
Q1 20	$9.0K
Q3 20	$17.0K
Q1 21	$8.0K
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$3M
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q2 24	$0
Q2 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-29.7%
Q2 22	—	-35.4%
Q3 22	—	-44.3%
Q4 22	-0.1%	-51.8%
Q1 23	+29.4%	-33.2%
Q2 23	+29.4%	-33.2%
Q3 23	+29.8%	-38.6%
Q4 23	+29.8%	-38.6%
Q2 24	+14.3%	-41.3%
Q2 25	-100.0%	-72.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 19	$0	—
Q1 20	$3M	—
Q3 20	$2M	—
Q1 21	$0	0.0%
Q1 22	$0	0.0%
Q2 22	$0	0.0%
Q3 22	$833.0K	246.8%
Q4 22	$833.0K	246.8%
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$385.0K	87.9%
Q4 23	$385.0K	87.9%
Q2 24	$0	0.0%
Q2 25	$145.0K	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 19	$13M	$3M
Q1 20	$14M	$3M
Q3 20	$9M	$7M
Q1 21	$11M	$6M
Q1 22	$7M	$4M
Q2 22	$7M	$4M
Q3 22	$6M	$3M
Q4 22	$6M	$3M
Q1 23	$5M	$3M
Q2 23	$5M	$3M
Q3 23	$3M	$3M
Q4 23	$3M	$3M
Q2 24	$2M	$2M
Q2 25	$1M	$947.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$31M	$21M	$52M
Q2 22	$31M	$21M	$52M
Q3 22	$34M	$3M	$37M
Q4 22	$34M	$3M	$37M
Q1 23	$13M	$2M	$15M
Q2 23	$13M	$2M	$15M
Q3 23	$5M	$0	$5M
Q4 23	$5M	$0	$5M
Q1 24	$8M	$6M	$14M
Q2 24	$8M	$6M	$14M
Q3 24	$3M	$0	$3M
Q4 24	$3M	$0	$3M
Q1 25	$7M	$2M	$9M
Q2 25	$10M	$0	$10M
Q3 25	$12M	$141.0K	$13M
Q4 25	$8M	$5M	$13M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 19	27M	—	—
Q1 20	28M	+2.2%	—
Q3 20	30M	+9.3%	—
Q1 21	39M	+28.7%	—
Q1 22	39M	+0.2%	+44.0%
Q2 22	39M	0.0%	+40.9%
Q3 22	39M	+0.1%	+29.1%
Q4 22	39M	0.0%	+0.3%
Q1 23	39M	-0.4%	-0.2%
Q2 23	39M	0.0%	-0.2%
Q3 23	39M	+0.1%	-0.3%
Q4 23	39M	0.0%	-0.3%
Q2 24	39M	+0.1%	+0.2%
Q2 25	40M	+3.2%	+3.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 19	$0	61
Q1 20	$0	61
Q3 20	$0	61
Q1 21	$3.7K	91
Q1 22	$4.4K	76
Q2 22	$4.4K	76
Q3 22	$4.4K	76
Q4 22	$5.0K	67
Q1 23	$6.5K	67
Q2 23	$6.5K	67
Q3 23	$6.5K	67
Q4 23	$12.5K	35
Q2 24	$14.3K	35
Q2 25	$0	40

Revenue / Employee